Interleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis

Authors:

Abstract
Sepsis remains a global health crisis with high mortality, due to a paucity of reliable diagnostic markers for accurate risk stratification and precision management. Interleukin‐39 (IL‐39), a novel immunomodulatory cytokine, plays an important role in regulating the pathophysiology of immunity, metabolism, and et al. Here, we observed significantly elevated serum IL‐39 levels in septic patients at admission compared with non‐sepsis ICU patients and healthy controls across two independent cohorts. Furthermore, circulating IL‐39 concentrations could predict 28‐days survival in patients with sepsis. Single‐cell sequencing demonstrated that elevated IL‐39 was derived from macrophages during sepsis. Meanwhile, supplementation of IL‐39, via either recombinant protein (rmIL‐39) administration or macrophage‐specific AAV‐mediated overexpression, profoundly aggravates multiple organ dysfunction and damage in septic mice. Consistently, macrophage IL‐39 deficiency, via either macrophage‐conditional knockout or macrophage‐specific AAV‐mediated silence, protects against sepsis. Mechanistically, IL‐39 engages GP130 to trigger MAPK/P38 signaling, driving pro‐inflammatory cytokine production. Consequently, macrophage‐specific GP130 deletion abrogates IL‐39‐induced sepsis aggravation. Finally, pharmaceutical inhibition of IL‐39 with neutralizing antibodies can protect against sepsis. Together, these results highlight the dual clinical utility of IL‐39, as both a robust biomarker with independent prognostic value for sepsis patient stratification and a promising therapeutic strategy for sepsis.
Funding Information
  • National Natural Science Foundation of China (82202378)
  • National Natural Science Foundation of China (82270098)

This publication has 24 references indexed in Scilit: